Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Casimiro
Danilo R
DR
Department of Viral Vaccine Research, Merck Research Laboratories, Merck & Co., 770 Sumneytown Pike, West Point, PA 19486, USA. danilo_casimiro@merck.com
Bett
Andrew J
AJ
Fu
Tong-ming
TM
Davies
Mary-Ellen
ME
Tang
Aimin
A
Wilson
Keith A
KA
Chen
Minchun
M
Long
Romnie
R
McKelvey
Troy
T
Chastain
Michael
M
Gurunathan
Sanjay
S
Tartaglia
Jim
J
Emini
Emilio A
EA
Shiver
John
J
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D000818:Animals; D015683:Gene Products, gag / Q000276:immunology*; D005822:Genetic Vectors; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000378:metabolism; D008253:Macaca mulatta; D011212:Poxviridae / Q000235:genetics* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014779:Virus Replication
D016915:AIDS Vaccines; D015683:Gene Products, gag; D007371:Interferon-gamma